Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5357
Abstract: Immunotherapy has exhibited efficacy in thymic carcinoma patients; however, there are insufficient data to confirm this efficacy in thymoma. The toxicity of immunotherapy also remains to be determined. read more here.
Keywords: immunotherapy; safety immunotherapy; efficacy; analysis efficacy ... See more keywords
Exploration of immunotherapy in advanced pulmonary lymphoepithelioma‐like carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Cancer"
DOI: 10.1002/ijc.34426
Abstract: Pulmonary lymphoepithelioma‐like carcinoma (PLELC) is a rare and histologically distinctive subtype of nonsmall cell lung cancer (NSCLC). High expression of programmed death ligand 1 (PD‐L1) and scarcity of druggable driver mutations raise the potential of… read more here.
Keywords: immunotherapy advanced; pulmonary lymphoepithelioma; immunotherapy; like carcinoma ... See more keywords
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
Sign Up to like & getrecommendations! Published in 2020 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2020.103167
Abstract: Advanced hepatocellular carcinoma (HCC) is the most frequent liver cancer. Immunotherapy has been explored in this disease in order to improve survival outcomes. Nowadays, scientific research is focusing especially on immune checkpoint inhibitors, in particular… read more here.
Keywords: hepatocellular carcinoma; immunotherapy; immunotherapy advanced; advanced hepatocellular ... See more keywords
Immunotherapy in advanced anal cancer: Is the beginning of a new era?
Sign Up to like & getrecommendations! Published in 2022 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2022.102373
Abstract: For decades metastatic squamous cell carcinoma of the anus (SCCA)has been considered a rare disease with very limited treatment options and a dismal prognosis. Prior to 2017, no data from prospective studies on the management… read more here.
Keywords: cancer; advanced anal; immunotherapy advanced; anal cancer ... See more keywords
Immunotherapy in advanced non-small-cell lung cancer (NSCLC) after progression on chemotherapy: real-world results from a prospective institutional cohort.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2021-0170
Abstract: Objective: To analyze the outcomes of patients receiving immunotherapy (IO) with advanced non-driver mutated non-small-cell lung cancer (NSCLC) after progression on systemic treatment. Methods: The overall survival (OS), progression-free survival (PFS) and best response to… read more here.
Keywords: non small; progression; small cell; immunotherapy advanced ... See more keywords
Immunotherapy in Advanced Prostate Cancer—Light at the End of the Tunnel?
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23052569
Abstract: Immunotherapeutic treatment approaches are now an integral part of the treatment of many solid tumors. However, attempts to integrate immunotherapy into the treatment of prostate cancer have been disappointing so far. This is due to… read more here.
Keywords: prostate cancer; cancer light; immunotherapy advanced; tumor ... See more keywords
Immunotherapy for advanced or recurrent hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "World Journal of Gastrointestinal Oncology"
DOI: 10.4251/wjgo.v15.i3.405
Abstract: Hepatocellular carcinoma (HCC) is associated with high morbidity and mortality, and is prone to intra- and extrahepatic metastasis due to the anatomical and functional characteristics of the liver. Due to the complexity and high relapse… read more here.
Keywords: hepatocellular carcinoma; recurrent hepatocellular; therapy; advanced recurrent ... See more keywords
Immunotherapy in Advanced Lung Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Oncology"
DOI: 10.46883/onc.2020.3407.0272
Abstract: Historically, platinum-based chemotherapy was the standard of care for metastatic lung cancer. However, since the success of immune checkpoint inhibitors (ICIs) in melanoma, PD-1/PD-L1 and CTLA-4 immune checkpoint pathways have been established as effective therapies… read more here.
Keywords: standard care; immunotherapy advanced; lung; lung cancer ... See more keywords